Literature DB >> 22205192

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.

K R Crews1, A Gaedigk, H M Dunnenberger, T E Klein, D D Shen, J T Callaghan, E D Kharasch, T C Skaar.   

Abstract

Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine as an analgesic are governed by CYP2D6 polymorphisms. Codeine has little therapeutic effect in patients who are CYP2D6 poor metabolizers, whereas the risk of morphine toxicity is higher in ultrarapid metabolizers. The purpose of this guideline (periodically updated at http://www.pharmgkb.org) is to provide information relating to the interpretation of CYP2D6 genotype test results to guide the dosing of codeine.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22205192      PMCID： PMC3289963          DOI： 10.1038/clpt.2011.287

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  40 in total

1.  A rapid and simple CYP2D6 genotyping assay--case study with the analgetic tramadol.

Authors:  Jürgen Borlak; Robert Hermann; Katharina Erb; Thomas Thum
Journal:  Metabolism       Date:  2003-11       Impact factor: 8.694

2.  Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data.

Authors:  A Gaedigk; R R Gotschall; N S Forbes; S D Simon; G L Kearns; J S Leeder
Journal:  Pharmacogenetics       Date:  1999-12

3.  Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes.

Authors:  C Mignat; U Wille; A Ziegler
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

4.  Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation.

Authors:  Tuija Heikkinen; Ulla Ekblad; Pertti Palo; Kari Laine
Journal:  Clin Pharmacol Ther       Date:  2003-04       Impact factor: 6.875

5.  The hypoalgesic effect of tramadol in relation to CYP2D6.

Authors:  L Poulsen; L Arendt-Nielsen; K Brøsen; S H Sindrup
Journal:  Clin Pharmacol Ther       Date:  1996-12       Impact factor: 6.875

6.  Impact of CYP2D6 genotype on postoperative tramadol analgesia.

Authors:  Ulrike M Stamer; Katja Lehnen; Fabienne Höthker; Bettina Bayerer; Stephanie Wolf; Andreas Hoeft; Frank Stuber
Journal:  Pain       Date:  2003-09       Impact factor: 6.961

7.  CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone.

Authors:  S V Otton; M Schadel; S W Cheung; H L Kaplan; U E Busto; E M Sellers
Journal:  Clin Pharmacol Ther       Date:  1993-11       Impact factor: 6.875

8.  Pregnancy-induced increase in metoprolol metabolism.

Authors:  S Högstedt; B Lindberg; D R Peng; C G Regårdh; A Rane
Journal:  Clin Pharmacol Ther       Date:  1985-06       Impact factor: 6.875

9.  Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism.

Authors:  Michael H Court; Soundarajan Krishnaswamy; Qin Hao; Su X Duan; Christopher J Patten; Lisa L Von Moltke; David J Greenblatt
Journal:  Drug Metab Dispos       Date:  2003-09       Impact factor: 3.922

10.  Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study.

Authors:  Trine Naalsund Andreassen; Ingrid Eftedal; Pål Klepstad; Andrew Davies; Kristin Bjordal; Staffan Lundström; Stein Kaasa; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2011-07-07       Impact factor: 2.953
View more
  132 in total

Review 1.  Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.

Authors:  Jacob T Brown; Jeffrey R Bishop; Katrin Sangkuhl; Erika L Nurmi; Daniel J Mueller; Jean C Dinh; Andrea Gaedigk; Teri E Klein; Kelly E Caudle; James T McCracken; Jose de Leon; J Steven Leeder
Journal:  Clin Pharmacol Ther       Date:  2019-04-13       Impact factor: 6.875

Review 2.  Drug interactions with triptans : which are clinically significant?

Authors:  Paul E Rolan
Journal:  CNS Drugs       Date:  2012-11       Impact factor: 5.749

3.  In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.

Authors:  Daniel L Hertz; Anna C Snavely; Howard L McLeod; Christine M Walko; Joseph G Ibrahim; Steven Anderson; Karen E Weck; Gustav Magrinat; Oludamilola Olajide; Susan Moore; Rachel Raab; Daniel R Carrizosa; Steven Corso; Garry Schwartz; Jeffrey M Peppercorn; James P Evans; David R Jones; Zeruesenay Desta; David A Flockhart; Lisa A Carey; William J Irvin
Journal:  Br J Clin Pharmacol       Date:  2015-08-02       Impact factor: 4.335

Review 4.  Toward a Global Roadmap for Precision Medicine in Psychiatry: Challenges and Opportunities.

Authors:  Shareefa Dalvie; Nastassja Koen; Nathaniel McGregor; Kevin O'Connell; Louise Warnich; Raj Ramesar; Caroline M Nievergelt; Dan J Stein
Journal:  OMICS       Date:  2016-09-16

Review 5.  Pharmacogenomics: personalizing pediatric heart transplantation.

Authors:  Sara L Van Driest; Steven A Webber
Journal:  Circulation       Date:  2015-02-03       Impact factor: 29.690

Review 6.  Adverse effects of analgesics commonly used by older adults with osteoarthritis: focus on non-opioid and opioid analgesics.

Authors:  Christine K O'Neil; Joseph T Hanlon; Zachary A Marcum
Journal:  Am J Geriatr Pharmacother       Date:  2012-10-02

7.  Abuse liability and reinforcing efficacy of oral tramadol in humans.

Authors:  Shanna Babalonis; Michelle R Lofwall; Paul A Nuzzo; Anthony J Siegel; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2012-10-23       Impact factor: 4.492

8.  Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors.

Authors:  Sonam Puri; Kelly A Hyland; Kristine Crowe Weiss; Gillian C Bell; Jhanelle E Gray; Richard Kim; Hui-Yi Lin; Aasha I Hoogland; Brian D Gonzalez; Ashley M Nelson; Anita Y Kinney; Stacy M Fischer; Daneng Li; Paul B Jacobsen; Howard L McLeod; Heather S L Jim
Journal:  Support Care Cancer       Date:  2018-03-15       Impact factor: 3.603

Review 9.  Relating human genetic variation to variation in drug responses.

Authors:  Ashraf G Madian; Heather E Wheeler; Richard Baker Jones; M Eileen Dolan
Journal:  Trends Genet       Date:  2012-07-26       Impact factor: 11.639

10.  Cytochrome P450 2D6 polymorphisms and predicted opioid metabolism in African American children with sickle cell disease.

Authors:  Marianne M Yee; Cassandra Josephson; Charles E Hill; Rosiland Harrington; Marta-Inés Castillejo; Ruan Ramjit; Ifeyinwa Osunkwo
Journal:  J Pediatr Hematol Oncol       Date:  2013-10       Impact factor: 1.289
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.